tt banner universal


Rabbi's Message

Jerry Cutler

Rabbi Benjamin Blech is a highly respected rabbi, teacher and author. I have known him for many years and thought that this month I would introduce him to you via the following article he wrote some years ago.
Love is in the air.

With the advent of Valentine's Day, the United States Greeting Card Association estimates that roughly 1,000,000,000 greeting cards filled with declarations of love are sent worldwide - and that number doesn't include the flowers, chocolates, jewelry and gifts that have become part of the rituals of this day on the calendar dedicated to expressing the emotion that Shakespeare called "the language of the soul."

As Jews, we may not be sure whether it's proper for us to join the party. After all, for the longest time the full name of this holiday was "St. Valentine's Day" because of its legendary link with the apocryphal story of one of the earliest Christian saints. Yet academics aren't the only ones who have recognized the dubious historical basis of this connection. Vatican II, the landmark set of reforms adopted by the Catholic Church in 1969, removed Valentine's Day from the Catholic church's calendar, asserting that "though the memorial of St. Valentine is ancient... apart from his name nothing is known... except that he was buried on the Via Flaminia on 14 February."
What's left for this day, as proponents of its universal celebration declare, is something that people of all faiths may in good conscience observe: A day in which to acknowledge the power of love to make us fully human.

When I am asked as a rabbi if I think it's a good idea for Jews to celebrate Valentines Day, my standard answer is, "Yes, we should celebrate love... every day of the year."

And as long as one day has been singled out to emphasize the meaning of love, this might be a wonderful moment for us as Jews to remind ourselves of its deeper meaning as a commandment - a meaning that is all too often lost when it's defined by Hallmark.

Love, for at least one of the major Talmudic Sages, represents the ultimate mitzvah. When a non-Jew asked Hillel to "teach the entire Torah on one foot," i.e. to summarize its essence, his response was basically the idea implicit in "love your neighbor as yourself."

Rabbi Jerry Ram Cutler

Shabbat Shalom

Our Next Shabbat Service

7:30 pm on Friday, 
February 1, 2019 
Why?  Tradition!

Going west on Wilshire as you approach Warner Blvd., one long block west of Beverly Glen, turn into the driveway that has the sign "Church Parking" and park on levels P2 or P3. Take the elevator up to P1 (which is also the lobby). Services are in the Town Hall room directly across from the elevator.

Arne's Corner

To my way of thinking, is it not extraordinary that  Congressional Democrats have been virtually silent and done nothing to c riticize, censure, disassociate themselves,  or in some way distance 
themselves from Reps. Rashida Talib (D-MI), Ihlan Omar (D-MN) on account  of their  anti-Semitic opposition to Israel's existence and their extreme,  repetitive anti-Israel words and deeds? Congressional Democrats have  also never called out Alexandria Ocasio-Cortez (D-NY) for her false  claims about Israel  committing a massacre in Gaza or her backtracking  on supporting Israel's existence.

                Why has the Democratic Party not called out these new 
freshmen Congressional colleagues who engage in vicious hostility 
towards Israel?

                Why have the Democrats never criticized and then, even 
elected Israel hater and Farrakhan acolyte (Keith Ellison) to be Deputy 
Director of the Democratic Party?

                Why have  the Democrats never criticized the 
Congressional Black Caucus for meeting with anti-Semite Louis Farrakhan?

                Why are Democrats seeking Israel hater Al Sharpton's 

                Why have they voted this week to stop anti-BDS legislation?

                I am very concerned  that their deafening silence is  allowing anti-Semitism to be dangerously mainstreamed and legitimized.  Oh where have you gone, Harry Truman, JFK and MLK?
 Arnold Charitan

As you know, I do not personally ascribe to everything our esteemed president writes. Please know that it is not CAT's policy to become political or to favor one party over another. However, CAT's president, Arne, has lots to say and hopes - as do I - that someone like Dan Paulson or Lou Zigman, countermands his views so that we can have an open discussion and air out our differences.

As a liberal Temple, we must be open to all members and hash our thoughts especially now when our country seems to be split on opposite sides of the spectrum. Perhaps then, our discussions won't get so vociferous and angry and we can learn to listen and forgive.

As for me, I love you all regardless of your party affiliation. Peace, brothers and sisters and a pleasant and joy filled Shabbat to you all.

Rabbi Jerry

Renew Ralphs Community Contributions Now!

grocery cart
Please Register today!
For your convenience, step-by-step website registration instructions can be found at, click on Community, click on Community Contributions, click on 'Enroll Now'. 

If you don't have computer access, please call Ralphs at 1-800-443-4438 for assistance.

CAT NPO# 92136
Ralphs Rewards Card
Donate to CAT while you grocery shop

Participants are required to register for the new term online at  or by calling Ralphs at  1-800-443-4438. 

You will be asked for The Creative Arts Temple NPO number. It is NPO# 92136

Please Note!!
The Scan Bar letters will no longer work at the register.

To verify if Creative Arts Temple is your charity of choice, look at the very bottom of your receipt next time you shop at Ralph's.  It should say "At your request, Ralph's is donating to Creative Arts Temple."  If you do not see that, you will need to register through the Ralph's 

Gelson's Discount Cards

Yes, it is Hanukkah again!  Gelson's has offered to provide the temple with discount coupons.  Pick them up at a Friday night service or call the temple for your coupon.  Gelson's will honor any expired coupon.  Take one or a few!

Do you shop on Amazon?
Support CAT when you shop on Amazon!

If you want Amazon to donate to Creative Arts Temple, you need to start each shopping session at and they will donate 0.5% of the price of your eligible purchases.

Monthly Events
Services, Dinners, High Holidays 
( Dates are subject to change)


Friday - February 1, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Friday - March 1, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Friday - April 5, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

F riday - May 3, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Friday - June 7, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Friday - July 5, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Friday - August 2, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Friday - September 6, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Monday - September 30, @ 8:00 pm
Rosh Hashanah Services 

Tuesday - October 1, @ 10:00 am
Rosh Hashanah Services 

Wednesday - October 2, @ 11:00 am
Tashlich By The Sea

Tuesday - October 8, @ 8:00 pm
Kol Nidre Services 

Wednesday - October 9, @ 10:00 am
Yom Kippur Services

Friday - November 1, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

Friday - December 6, @ 7:30 pm
Shabbat Services 
Belmont Village - Town Hall
10475 Wilshire Blvd

131 S. Rodeo Drive  Suite 100
Beverly Hills, CA 90212
Cell 310-995-0340
Bus 310-248-6440

I will be with you every step of the way. That is my promise, that is my commitment. 

Also, a FREE mezuzah hanging on your new home from our esteemed Rabbi. 


Follow me on
Clickable Links

grumpy cat hearts
February Anniversaries
Mazel Tov to our CAT lovebirds!

Barry & Cindy Smith 2/14/2019
Nathan & Elaine Sperling 2/14/2019

February  Birthdays
And many happy returns!
bday grumpy cat         

Sara Silver 2/2/2019
Doris Felsen 2/4/2019
Dimitry Svetlitsa 2/6/2019
Tootsie Veprin 2/10/2019
Debby Bittecks 2/18/2019
Aaron Bush 2/19/2019
Eunice Brown 2/20/2019
Joel Diamond 2/20/2019
Barbara Lee Schulz 2/21/2019
Dale G. Pressman 2/22/2019

cake platter
January Onegs
Thank you to our sponsors!

Sherwyn & Edythe Horwitz In honor of their anniversary

As always, thank you to our annual oneg sponsor:  ARNOLD & GLADYS CHARITAN 

Get Wells
Refuah Shleima

CAT wishes speedy recoveries to


The Creative Arts Temple sadly announces the passing of

Lee Mintz,  father of one of our members, Mallory Sobel.

The Creative Arts Temple sends our deepest condolences to the Sobel family. 

January Yahrzeits 
May you be comforted by the mourners of Zion

Lois Bennett In memory of Sydney Bennett
Ralph & Cynthia Bovitz In memory of Sam Bovitz & Anne Yasser
Stephen Ellman In memory of Doris Ellman Cohen & Leslie Ellman
Irene Graff In memory of Paul Graff
Evelyn Gray In memory of Martin Gray
Harry & Leann Hiles In memory of Zelda Balarsky
Persten, Barbara In memory of Katelyn Victoria Persten
Persten, Barbara In memory of Mattie, Sherman, Barry, Peter, and Alyce Block
Ann Radow In memory of Eddie Radow
Phyllis Spear  & Irwin Schwartzman In memory of Sam Gomberg  & Sy Gomberg
Carole Speer In memory of Jack and Judy Trystman
Emory & Lucy Weltsch In memory of Riza Weltsch

If you made a donation in memory of your loved one and you don't see it here, it is because it was received after publication deadline and will appear next month

News of the Day


"Our results are consistent and repeatable."
 JANUARY 28, 2019 23:14

A small team of Israeli scientists think they might have found the first complete cure for cancer.

"We believe we will offer in a year's time a complete cure for cancer," said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000 in the ITEK incubator. AEBi developed the SoAP platform, which provides functional leads to very difficult targets.

"Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market," Aridor said. "Our solution will be both generic and personal."

It sounds fantastical, especially considering that an estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer. Further, every sixth death in the world is due to cancer, making it the second leading cause of death (second only to cardiovascular disease).

Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic - a disruption technology of the highest order.

The potentially game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies. It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage - a virus that infects bacteria. That protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.

In 2018, a team of scientists won the Nobel Prize for their work on phage display in the directed evolution of new proteins - in particular, for the production of antibody therapeutics.

AEBi is doing something similar but with peptides, compounds of two or more amino acids linked in a chain. According to Morad, peptides have several advantages over antibodies, including that they are smaller, cheaper, and easier to produce and regulate.

When the company first started, Morad said, "We were doing what everyone else was doing, trying to discover individual novel peptides for specific cancers." But shortly thereafter, Morad and his colleague, Dr. Hanan Itzhaki, decided they wanted to do something bigger.

To get started, Morad said they had to identify why other cancer-killing drugs and treatments don't work or eventually fail. Then, they found a way to counter that effect.

For starters, most anti-cancer drugs attack a specific target on or in the cancer cell, he explained. Inhibiting the target usually affects a physiological pathway that promotes cancer. Mutations in the targets - or downstream in their physiological pathways - could make the targets not relevant to the cancer nature of the cell, and hence the drug attacking it is rendered ineffective.

In contrast, MuTaTo is using a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically. By using at least three targeting peptides on the same structure with a strong toxin, Morad said, "we made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer."

"The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used," Morad continued. "Instead of attacking receptors one at a time, we attack receptors three at a time - not even cancer can mutate three receptors at the same time."

Furthermore, many cancer cells activate detoxification mechanisms when in stress from drugs. The cells pump out the drugs or modify them to be non-functional. But Morad said detoxification takes time. When the toxin is strong, it has a high probability of killing the cancer cell before detoxification occurs, which is what he is banking on.

Many cytotoxic anticancer treatments aim at fast-growing cells. But cancer stem cells are not fast growing, and they can escape these treatments. Then, when the treatment is over, they can generate cancer again. "If it does not completely annihilate the cancer, the remaining cells can start to get mutations again, and then the cancer comes back, but this time it is drug resistant," Morad said.

He explained that because cancer cells are born out of mutations that occur in cancer stem cells, most of the overexpressed proteins which are targeted on the cancer cell exist in the cancer stem cells. MuTaTo's multiple-target attack ensures that they will be destroyed as well.

Finally, some cancer tumors erect shields which create access problems to large molecules, such as antibodies. MuTaTo acts like an octopus or a piece of spaghetti and can sneak into places where other large molecules cannot reach. Morad said the peptide parts of MuTaTo are very small (12 amino acids long) and lack a rigid structure.

"This should make the whole molecule non-immunogenic in most cases and would enable repeated administration of the drug," he said.

Morad said their discovery could also reduce the sickening side-effects of most cancer treatments, which stem from drug treatments interacting with the wrong or additional targets, or the correct targets but on non-cancerous cells. He said MuTaTo's having a combination of several highly specific cancer-targeting peptides on one scaffold for each type of cancer cell would increase the specificity to the cancer cell due to the avidity effect. In addition, in most cases, the non-cancer cells that have a protein in common with the cancer cells do not overexpress it.

"This makes a great difference between the two kinds of cells and should decrease the side effects dramatically," Morad said.

He equated the concept of MuTaTo to the triple drug cocktail that has helped change AIDS from being an automatic death sentence to a chronic - but often manageable - disease.

Today, AIDS patients take protease inhibitors in combination with two other drugs called reverse transcriptase inhibitors. The drug combination disrupts HIV at different stages in its replication, restrains an enzyme crucial to an early stage of HIV duplication and holds back another enzyme that functions near the end of the HIV replication process.

"We used to give AIDS patients several drugs, but we would administer them one at a time," Morad explained. "During the course of treatment, the virus mutated, and the AIDS started attacking again. Only when patients started using a cocktail, were they able to stop the disease."

Now, he said, people with AIDS are HIV carriers, but they are not sick anymore.

The MuTaTo cancer treatment will eventually be personalized. Each patient will provide a piece of his biopsy to the lab, which would then analyze it to know which receptors are overexpressed. The individual would then be administered exactly the molecule cocktail needed to cure his disease.
However, unlike in the case of AIDS, where patients must take the cocktail throughout their lives, in the case of MuTaTo, the cells would be killed, and the patient could likely stop treatment after only a few weeks.

The company is now writing patents on specific peptides, which will be a large bank of targeting toxin peptides wholly owned and hard to break, said Aridor.

Morad said that so far, the company has concluded its first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials. AEBi is on the cusp of beginning a round of clinical trials which could be completed within a few years and would make the treatment available in specific cases.

Aridor added: "Our results are consistent and repeatable."

Please make a note the Creative Arts Temple has a new phone number as of July 27, 2018. 

Our new phone number is  818-855-1301.  

Our address is:

Creative Arts Temple
P.O. Box 241831
Los Angeles, CA 90024

Creative Arts Temple

P.O. Box 241831
Los Angeles, CA 90024

(818) 855-1301
                               Like us on Facebook        View our videos on YouTube